产超广谱β-内酰胺酶肠杆菌血行感染的危险因素分析

杨静; 林芳; 于云鹏; 咸会波; 司君利

doi:10.13201/j.issn.1009-5918.2019.09.010

产超广谱β-内酰胺酶肠杆菌血行感染的危险因素分析

- 青岛市市立医院急诊科(山东青岛,266000)

详细信息

通讯作者: 司君利,E-mail:junlisi@163.com

中图分类号: R472

收稿日期: 2019-07-21

Analysis of risk factors for the bloodstream infection of enterobacteriaceae bacteria producing extended spectrum β-lactamase

- Department of Emergency, Qingdao Municipal Hospital, Qingdao, Shandong, 266000, China

More Information

Corresponding author: SI Junli, E-mail: junlisi@163.com

Received Date: 21 July 2019

摘要

摘要: 目的: 研究产超广谱β-内酰胺酶(ESBLs)肠杆菌血行感染的危险因素。方法: 回顾性分析233例血培养结果示肠杆菌科类细菌生长的患者病历资料,详细记录基线资料,分析产超广谱β-内酰胺酶肠杆菌科血行感染的危险因素。结果: 年龄(OR:0.935,95%CI:0.887~0.985)、APACHEⅡ评分(OR:1.408,95%CI:1.269~1.563)、感染大肠埃希菌(OR:4.274,95%CI:1.225~14.916)、侵袭性的医疗操作(OR:0.377,95%CI:0.150~0.947)以及三代头孢菌素的暴露(OR:0.254,95%CI:0.071~0.906)是产ESBLs肠杆菌血行感染的重要独立危险因素。结论: 患者病情严重程度、感染状态、初始经验性抗菌治疗方案以及医疗侵袭性操作,都会使产ESBLs肠杆菌血行感染的风险增加,因此,有必要根据患者的不同病情做出合理的临床决策,并选择合适的抗菌药物。
- 超广谱β-内酰胺酶 /
- 肠杆菌科 /
- 血行感染 /
- 危险因素
Abstract: Objective: To study the risk factors for the bloodstream infection of enterobacteriaceae bacteria producing extended spectrum β-lactamases(ESBLs). Method: This retrospective study included 233 patients whose blood culture results showed that they were infected with Enterobacteriaceae bacterial. Their medical records and baseline data were recorded in detail and the risk factors for ESBLs-producing Enterobacteriaceae infection were analyzed. Result: Age(OR:0.935, 95%CI:0.887~0.985), APACHE-II score(OR:1.408, 95%CI:1.269~1.563), infection with E. coli(OR:4.274, 95%CI:1.225~14.916), invasive medical procedures(OR:0.377, 95%CI:0.150~0.947) and exposure to third-generation cephalosporins(OR:0.254, 95%CI:0.071~0.906) were important independent risk factors for ESBLs-producing enterobacteriaceae bacteria infection.Conclusion: The severity of the disease, the state of infection, the initial empirical antibacterial treatment, and the medical invasive procedure will increase the risk of infection of ESBLs-producing enterobacteriaceae bacteria. Therefore, it is necessary to make reasonable clinical decisions according to the patient's condition,and choose the right antibacterial drug.
- extended spectrum β-lactamases /
- enterobacteriaceae /
- bloodstream infection /
- risk-factor

HTML全文

参考文献(16)

[1]	杨祖耀,詹思延,王波,等.中国血流感染住院病死率的系统评价和meta分析[J].北京大学学报(医学版),2010,42(3):304-307.
[2]	Hsueh PR,Badal RE,Hawser SP,et al.Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region:2008 results from SMART(Study for Monitoring Antimicrobial Resistance Trends)[J].Int J Antimicrob Agents,2010,36(5):408-414.
[3]	马越,李景云,金少鸿.美国临床实验室标准委员会推荐药敏试验操作方法和判断标准(2005年修订版)[J].中华医学杂志,2005,85(17):1182-1184.
[4]	Perez F,Endimiani A,Hujer KM,et al.The continuing challenge of ESBLs[J].Curr Opin Pharmacol,2007,7(5):459-469.
[5]	周梦兰,杨启文,于淑颖,等.血流感染流行病学研究进展[J].中国感染与化疗杂志,2019,19(2):212-217.
[6]	Rupp ME,Fey PD.Extended spectrum beta-lactamase(ESBL)-producing Enterobacteriaceae:considerations for diagnosis,prevention and drug treatment.[J].Drugs,2003,63(4):353-365.
[7]	张杰,黄湘宁,龙姗姗,等.四川省细菌耐药监测网2016年血流感染病原菌分布和耐药分析[J].中国循证医学杂志,2017,17(9):1011-1014.
[8]	张博佳,谈敏,袁应华,等.肺部感染产超广谱β内酰胺酶肠杆菌科细菌的危险因素分析[J].同济大学学报(医学版),2018,39(2):117-122.
[9]	杨凤霞,徐志泉,王克强,等.产AmpC酶革兰阴性杆菌的分布及耐药性分析[J].中华医院感染学杂志,2009,19(13):1725-1727.
[10]	Nordmann P,Poirel L.The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide[J].Clin Microbiol Infect,2014,20(9):821-830.
[11]	Robicsek A,Jacoby GA,Hooper DC.The worldwide emergence of plasmid-mediated quinolone resistance[J].Lancet Infectious Dis,2006,6(10):629-640.
[12]	Hamzaoui Z,Ocampo-Sosa A,Fernandez Martinez M,et al.Role of association of OmpK35 and OmpK36 alteration and blaESBL and/or blaAmpCgenes in conferring carbapenem resistance among non-carbapenemase-producingKlebsiella pneumoniae[J].Int J Antimicrobial Agents,2018,52(6):898-905.
[13]	Muhammed M,Flokas ME,Detsis M,et al.Comparison Between Carbapenems and beta-Lactam/beta-Lactamase Inhibitors in theTreatment for Bloodstream Infections Caused by Extended-Spectrumbeta-Lactamase-Producing Enterobacteriaceae:A Systematic Review andmeta-Analysis[J].Open Forum Infect Dis,2017,4(2):x99.
[14]	Reinhart WH.The optimum hematocrit[J].Clin Hemorheol Microcirc,2016,64(4):575-585.
[15]	Xiao T,Wu Z,Shi Q,et al.A retrospective analysis of risk factors and outcomes in patients withextended-spectrum beta-lactamase-producing Escherichia coli bloodstreaminfections[J].J Global Antimicrobial Resistance,2019,17:147-156.
[16]	Superti SV,Augusti G,Zavascki A P.Risk factors for and mortality of extended-spectrum-beta-lactamase-producingKlebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections[J].Rev Inst Med Trop Sao Paulo,2009,51(4):211-216.